$5.250
-0.155 (-2.96%)收盘时
CTKB 资讯
CTKB 事件
Sysmex and Cytek Collaborate to Enhance Clinical Diagnostics
Sysmex Europe and Cytek Biosciences announced a strategic collaboration across over a dozen European countries to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions.
Cytek Biosciences Q2 Revenue at $48.14M
Reports Q2 revenue $48.14M, consensus $48.61M. "Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business," said Wenbin Jiang, CEO of Cytek Biosciences. "Looking ahead, our priorities remain clear: accelerating adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the remainder of 2026 and the long-term opportunity ahead."
Cytek Biosciences Raises 2026 Revenue Outlook to $207M-$212M
The company said, "Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million, assuming no change in current foreign currency exchange rates."
Cytek Biosciences Reports FY25 Revenue of $201M
Reports preliminary FY25 revenue $201M, consensus $196.71M. "Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025 and reflects a continuation of positive trends we saw emerging in the third quarter. These trends include a continuation of strong growth in Services, Reagents and Asia Pacific instrument revenue and an improvement in instrument revenue growth in the US and EMEA. We were particularly pleased to see a return to positive growth in our instrument sales in EMEA in the fourth quarter," said Dr. Wenbin Jiang, CEO of Cytek Biosciences. "With strong execution across our portfolio, we believe we are well positioned to deliver sustainable growth and profitability in a large flow cytometry market."
Morgan Stanley Initiates Coverage on Cytek Biosciences with Equal Weight Rating and $6 Price Target
Morgan Stanley assumed coverage of Cytek Biosciences with an Equal Weight rating and a price target of $6, up from $4. Life Science Tools and Diagnostics end market bright spots are beginning to emerge and the firm sees "plenty of catalysts" in the pipeline across its coverage, adding that it sees "lots to like in the space entering 2026." However, a recent industry valuation spike in the second half of the year leaves multiples in "a fair place," so the firm starts the group with an In-Line industry view, the analyst tells investors. Among the group, the analyst identifies Danaher (DHR) as Top Pick.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。